Skip to main content

Optimising outcomes for NICE assessment of new medicines

Optimising outcomes for NICE assessment of new medicines
Click to enlarge
Book Here   

A pharmaceutical market access specialist with more than 20 years’ experience of tracking access environments around the world. 

more about Neil

I am the founder of Oxygen - a strategic healthcare public affairs company based in the new diplomatic precinct of Nine Elms in London.

more about Henry

In his current consultancy position, Eric specialises in strategic market access, patient engagement, and life sciences and healthcare policy.

more about Eric

22 Jul 2022 13:00 - 14:00


Ian Chamberlain hosts July’s Think Tank where he'll discuss the optimising of outcomes for NICE assessment of new medicines.


For this 60-minute live event, Ian will be joined by three leading industry experts, Neil Grubert , Eric Low and Henry Burkitt .


Together, they will discuss the myths surrounding market access NICE / Health Technology Assessment ( HTA) submissions followed by a Q&A session.


By attending the session you’ll take away information surrounding:
  • What pharma gets wrong – and what it can do about it
  • What role government affairs play in an affective submission
  • How to build advocacy for a competitive edge
  • How to best integrate patients’ needs and voice into a submission

 Sign up today by filling out the form below: